Expert Methods On Baf-A1 Unveiled
The exclusion was condition specific for depression or fatigue and combined prescriptions for those with positive screening for both conditions. The summed duration of managed status was examined either by the total number of months a patient was managed (1�C12 months) in the regression analysis or by 3-month segments in the analysis of covariance (ANCOVA) (1�C3 months vs. 4�C6 months vs. 7�C9 months vs. 10�C12 months). Outcome Measures The primary outcome measure for all the analyses was adherence to MS medications as determined by the proportion of days covered (PDC) metric. At the patient level, the PDC was this website calculated as the total medication days' supply17,18 divided by the 365-day follow-up period.10 The PDC ranged from 0% to 100%, with higher values representing greater adherence. Adherence rates for participants in the CCMS program were contrasted with those for the matched control group, and a subanalysis Lumacaftor compared adherence rates for patients who also screened positive for depression or fatigue. Statistical Analyses For the primary objective, generalized estimating equation models were used to test for adherence differences between matched managed and less-managed patients with MS. Statistical significance was determined using the .05 alpha level. For the subanalysis, ANCOVA was used to examine the interaction of managed status and adverse health markers on mean adherence. To examine the impact of the same variables on a common adherence rate (PDC ��80%) in the subgroup, a logistic regression analysis was conducted. All the Resminostat statistical analyses were conducted using SAS software version 9.3 and included the same covariates of sex, age, previous comorbidity, and previous persistence with comorbid medications. Results Between December 1, 2010, and May 31, 2011, 8128 patients had an MS prescription filled at one of the study pharmacies (Figure 1). We excluded patients who had a prescription for one of the MS study medications during the 6 months before the study period, who did not have at least two prescriptions for an MS study medication during the study period, who participated in other MS programs, or who were younger than 18 years. The final study sample was 939 patients (Figure 1). After conducting one-to-many propensity score matching for the primary analysis, 235 managed patients and 470 less-managed patients remained, with no significant differences observed between the covariates (Table 1). For the combined groups, the mean age was 45 years, 84% were women, approximately 24% had one or more chronic conditions, and adherence to medications for chronic diseases at baseline was approximately 57%. Compared with less-managed patients (ie, those participating for
